Loading...

PE anti-mouse IL-2 Antibody

Pricing & Availability
Clone
JES6-5H4 (See other available formats)
Regulatory Status
RUO
Other Names
Interleukin-2, T cell growth factor (TCGF), Eosinophil differentiation factor (EDF), Killer cell helper factor (KHF), Macrophage-activating factor for cytotoxicity I (MAF-C I), Thymocyte differentiation factor (TDF)
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
JES6-5H4_PE_011108
PMA+ionomycin-stimulated C57BL/6 mouse splenocytes intracellular stained with with CD3 (17A2) APC and JES6-5H4 PE
  • JES6-5H4_PE_011108
    PMA+ionomycin-stimulated C57BL/6 mouse splenocytes intracellular stained with with CD3 (17A2) APC and JES6-5H4 PE
Compare all formats See PE spectral data
Cat # Size Price Quantity Check Availability Save
503807 25 µg £57
Check Availability


Need larger quantities of this item?
Request Bulk Quote
503808 100 µg £151
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

IL-2 is a potent lymphoid cell growth factor which exerts its biological activity primarily on T cells. Additionally, IL-2 has been found to stimulate growth and differentiation of B cells, NK cells, LAK cells, monocytes, and oligodendrocytes.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
E. coli-expressed, recombinant mouse IL-2
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

ICFC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

ELISA Detection1-3 or ELISPOT Detection4-6: The biotinylated JES6-5H4 antibody is useful as a detection antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with the purified JES6-1A12 antibody (Cat. Nos. 503701 & 503702) as capture antibody and recombinant mouse IL-2 (Cat. No. 575409) as the standard.
Flow Cytometry8-10: The fluorochrome-labeled JES6-5H4 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IL-2 -producing cells within mixed cell populations.
Neutralization1,7: The Ultra-LEAF™ purified antibody (Endotoxin in vivo and in vitro (Cat. No. 503845-503850)) is recommended for neutralization.
Additional reported applications (for the relevant formats) include: immunoprecipitation1, immunohistochemical staining of paraformaldehyde-fixed, saponin-treated frozen tissue sections2, in vivo capture7, and immunocytochemistry.
Note: For testing mouse IL-2 in serum, plasma or supernatant, BioLegend's ELISA MAX™ Sets (Cat. No. 431001 & 431004) are specially developed and recommended.

Application References

(PubMed link indicates BioLegend citation)
  1. Abrams J, et al. 1992. Immunol. Rev. 127:5.
  2. Sander B, et al. 1993. J. Immunol. Meth. 166:201.
  3. Abrams J. 1995. Curr. Prot. Immunol. John Wiley and Sons New York. Unit 6.20.
  4. Klinman D, et al. 1994. Curr. Prot. Immunol. John Wiley and Sons New York. Unit 6.19.
  5. Mo X, et al. 1995. J. Virol. 69:1288.
  6. Karulin A, et al. 2000. J. Immunol. 164:1862.
  7. Finkelman F, et al. 2003. Curr. Prot. Immunol. John Wiley & Sons New York. Unit 6.28.
  8. Ko SY, et al. 2005. J. Immunol. 175:3309. PubMed
  9. Kang SS and Allen PM. 2005. J. Immunol. 174:5382.
  10. Lawson BR, et al. 2007. J. Immunol. 178:5366.
Product Citations
  1. Elong Ngono A, et al. 2020. Cell Reports. 1.330555556. PubMed
  2. Hirai T, et al. 2020. Immunity. 54(1):84-98.e5. PubMed
  3. Chakraborty P, et al. 2022. Cancer Res. 82:1969. PubMed
  4. D'Angeli V, et al. 2022. Eur J Immunol. 52:1058. PubMed
  5. Dölz M, et al. 2022. iScience. 25:105372. PubMed
  6. Nanishi E, et al. 2023. NPJ Vaccines. 8:18. PubMed
  7. Shi X, et al. 2023. iScience. 26:106143. PubMed
  8. van Elsas MJ, et al. 2023. J Immunother Cancer. 11:. PubMed
  9. Seo YB, et al. 2023. Int J Mol Sci. 24:. PubMed
  10. Singer M et al. 2016. Cell. 166(6):1500-1511 . PubMed
  11. Page N, et al. 2018. Immunity. 48:937. PubMed
  12. Wilfahrt D, et al. 2021. Elife. 10:. PubMed
  13. Li X, et al. 2022. Nat Commun. 13:2794. PubMed
  14. Hamilton JAG, et al. 2021. Aging Cell. 20:e13309. PubMed
  15. Maschmeyer P, et al. 2017. J Autoimmun.. 10.1016/j.jaut.2017.11.005. PubMed
  16. Wei H, et al. 2021. Malar J. 20:89. PubMed
  17. Seo YB, et al. 2021. Vaccines (Basel). 9: . PubMed
  18. Yang C, et al. 2021. J Immunother Cancer. 9:. PubMed
  19. Duan Q, et al. 2021. Front Cell Dev Biol. 9:761193. PubMed
  20. Oda SK, et al. 2020. J Exp Med. 217: . PubMed
  21. Acharya N, et al. 2020. Immunity. 53(3):658-671.e6. PubMed
  22. Liang Q, et al. 2022. iScience. 25:104043. PubMed
  23. Liang Y, et al. 2020. J Immunol. 204:2984. PubMed
  24. Klarquist J, et al. 2021. Cell Rep. 36:109591. PubMed
  25. Wu M, et al. 2021. Nat Commun. 12:3500. PubMed
  26. Lercher A, et al. 2019. Immunity. 51:1074. PubMed
  27. Marangoni F, et al. 2021. Cell. . PubMed
  28. Zhuang Z, et al. 2021. J Exp Med. 218:00:00. PubMed
  29. Tanaka Y, et al. 2021. Int J Mol Sci. 22:. PubMed
  30. Shrivastava T, et al. 2021. Front Immunol. 12:641447. PubMed
  31. Dolina JS, et al. 2020. Cell Rep. 107249:31. PubMed
  32. Kelsey E Sivick et al. 2018. Cell reports. 25(11):3074-3085 . PubMed
  33. Chang Q, et al. 2020. Scand J Immunol. 92:e12877. PubMed
  34. Kim C, et al. 2019. Cell Rep. 29:2202. PubMed
  35. Ulrich-Lewis JT, et al. 2022. Front Immunol. 13:861710. PubMed
  36. Grigoryan L, et al. 2022. NPJ Vaccines. 7:55. PubMed
  37. Ringel AE, et al. 2020. Cell. 183(7):1848-1866.e26. PubMed
  38. Knocke S, et al. 2016. Cell Rep. 17:2234-2246. PubMed
  39. Ren Y, et al. 2022. J Immunother Cancer. 10:. PubMed
  40. White C, et al. 2015. J Immunol. 194:697. PubMed
  41. Kim MY, et al. 2017. Plant Biotechnol J. 1.729166667. PubMed
  42. Yan J, et al. 2020. Cell Rep. 107820:31. PubMed
  43. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  44. Ye X, et al. 2021. Cancer Biol Med. Online ahead of print. PubMed
  45. Toshiro Hirai et al. 2019. Immunity. 50(5):1249-1261 . PubMed
  46. Ma K, et al. 2022. iScience. 25:104347. PubMed
  47. Evgin L, et al. 2022. Sci Transl Med. 14:eabn2231. PubMed
  48. Majedi FS, et al. 2020. Biomaterials. 252:120058. PubMed
  49. Yan Q, et al. 2017. Molecular Immunology. 10.1016/j.molimm.2017.05.006. PubMed
  50. Wen J, et al. 2020. Cell Rep. 31:107566. PubMed
  51. Varikuti S, et al. 2020. Br J Cancer. 122:1005. PubMed
  52. Ma Q, et al. 2022. Vaccines (Basel). 10:. PubMed
  53. Kung YJ, et al. 2022. J Biomed Sci. 29:57. PubMed
  54. Nanishi E, et al. 2022. Commun Biol. 5:790. PubMed
  55. Sade–Feldman M, et al. 2018. Cell. 175:998. PubMed
  56. Haring J, et al. 2008. J Immunol. 180:2855. PubMed
  57. Sun Y, et al. 2020. J Immunol. 205:2649. PubMed
  58. Tzeng TT, et al. 2022. NPJ Vaccines. 7:60. PubMed
  59. Lu Y, et al. 2018. Cancer Cell. 33:1048. PubMed
  60. Ding Z, et al. 2017. Sci Rep. 10.1038/s41598-017-12488-z. PubMed
  61. Li J, et al. 2021. Cell Reports. 34(11):108839. PubMed
  62. Charlton J, et al. 2015. PLoS One. 10:119200. PubMed
  63. Teng F, et al. 2021. Cell Rep. 37:110051. PubMed
  64. Reguzova A, et al. 2020. Vaccines (Basel). 8:. PubMed
  65. Steinmann S, et al. 2020. Sci Rep. 1.160416667. PubMed
  66. Corrado M, et al. 2020. Cell Metab. 32:981. PubMed
  67. Laczkó D, et al. 2020. Immunity. 53:724. PubMed
  68. Liu Z, et al. 2022. Int J Nanomedicine. 17:1711. PubMed
RRID
AB_315301 (BioLegend Cat. No. 503807)
AB_315301 (BioLegend Cat. No. 503808)

Antigen Details

Structure
Cytokine; 15-30 kD (Mammalian)
Bioactivity
Proliferation of T lymphocytes, B cells, anti-inflammatory, hematopoiesis, tumor surveillance
Cell Sources
T cells
Cell Targets
T cells, B cells, NK cells, LAK cells, monocytes, macrophages, oligodendrocytes
Receptors
High affinity heterotrimer of IL-2Rα/β/γ, intermediate affinity homodimer IL-2Rα (CD25; p55; Tac) and heterodimer IL-2Rβ (CD122)/γ; γ-subunit (CD132) in common with IL-4R, IL-7R, IL-13R, IL-15R
Cell Type
Tregs
Biology Area
Immunology
Molecular Family
Cytokines/Chemokines
Antigen References

1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press San Diego.
2. Taniguchi T, et al. 1993. Cell 73:5.
3. Nistico G. 1993. Prog. Neurobiol. 40:463.
4. Waldmann T, et al. 1993. Ann. NY Acad. Sci. 685:603.

Regulation
Upregulated by NFAT; downregulated by TCF-8, CIF (colostrum inhibitory factor)
Gene ID
16183 View all products for this Gene ID
Specificity (DOES NOT SHOW ON TDS):
IL-2
Specificity Alt (DOES NOT SHOW ON TDS):
IL-2
App Abbreviation (DOES NOT SHOW ON TDS):
ICFC
UniProt
View information about IL-2 on UniProt.org

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.
Go To Top Version: 1    Revision Date: 11/30/2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account